3.73 CheckMate 577: Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

Plenary Session

Vinay Prasad, MD MPH

Health, Medicine, Policy, Oncology, Science & Medicine

4.7 • 789 Ratings

🗓️ 12 May 2021

⏱️ 16 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

On today's episode, we have a short monologue for you on the recent CheckMate 577 study that was recently published in the New England Journal of Medicine. The title of the paper is "Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer". CheckMate 577: doi.org/10.1056/NEJMoa2032125 Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

Transcript

Click on a timestamp to play from that location

0:00.0	Welcome to plenary session. I'm Dr. Vinay Prasad. I'm an associate professor at the University
0:10.7	California, San Francisco. My interests are medicine, hematology, oncology, and health policy,
0:16.7	and that's what you're going to get on this podcast.
0:23.7	This week, we got a great episode in store for you.
0:26.1	We've got a monologue, and I think you're going to really enjoy this.
0:30.0	But first, a plug.
0:33.3	If you like this podcast, check out the new website, www.
0:35.7	www. plenary session podcast.com.
0:39.5	We've got show notes, we've got trial summaries, we've got everything you could want on the website.
0:41.9	Follow us on Twitter at plenary underscore session.
0:45.2	Write a review for us on the iTunes store.
0:48.0	And become a supporter for this podcast on Patreon.
0:50.9	Patreon backers get access to the slides for presentations I give on plenary session. You also get a few bonus lectures. And with that, let's start the show.
1:06.5	All right, I'm back. We're recording. This is what I've promised. A little discussion of Checkmate 577.
1:14.4	So I read this paper. I read it a couple weeks ago. And I've been meaning to do this, but something keeps interrupting me. So I said, you know what? I'm just going to do it. I'm just going to wing it and say what I think about Checkmate 577, which is adjuvant and abelumab and resected esophageal or jean junction cancer. This is the New England Journal Medicine paper
1:31.6	April 1st. It has a laudatory editorial that says it is the standard of care. Nothing like
1:37.2	a New England Journal Medicine editorial to tell me that it is in fact the standard of care.
1:42.2	So what is Chuckmate 577? So this is a study of esophagus cancer.
1:46.2	It has squames.
1:46.9	It has adenos and GE Junction, where they are randomized basically after completing
1:52.8	the cross-trial protocol, carbopaclytexyl radiotherapy, chemo-radiotherapy.
1:58.9	They undergo surgical resection. Key point is they have to have pathologic, they have to have pathologic evidence of disease. They can't have had pathologic complete response. So that means you're excluding people who have PathCR. You have to have some disease either in the tumor or the nodes. And of course, we generally think
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from Vinay Prasad, MD MPH, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Vinay Prasad, MD MPH and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.